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Background: Chagas disease is endemic in Latin 
America and affects 8 million people worldwide. In 
2010, Catalonia introduced systematic public health 
surveillance to detect and treat congenital Chagas dis-
ease. Aim: The objective was to evaluate the health 
outcomes of the congenital Chagas disease screening 
programme during the first 6 years (2010–2015) after 
its introduction in Catalonia. Methods: In a surveillance 
system, we screened pregnant women and newborns 
and other children of positive mothers, and treated 
Chagas-positive newborns and children. Diagnosis 
was confirmed for pregnant women and children with 
two positive serological tests and for newborns with 
microhaematocrit and/or PCR at birth or serology at 
age 9 months. Results: From 2010 to 2015, the esti-
mated screening coverage rate increased from 68.4% 
to 88.6%. In this period, 33,469 pregnant women were 
tested for  Trypanosoma cruzi  and 937 positive cases 
were diagnosed. The overall prevalence was 2.8 cases 
per 100 pregnancies per year (15.8 in Bolivian women). 
We followed 82.8% of newborns until serological test-
ing at age 9–12 months and 28 were diagnosed with 
Chagas disease (congenital transmission rate: 4.17%). 
Of 518 siblings, 178 (34.3%) were tested and 14 (7.8%) 
were positive for  T. cruzi. Having other children with 
Chagas disease and the heart clinical form of Chagas 
disease were maternal risk factors associated with 
congenital T. cruzi  infection (p < 0.05). Conclusion: The 
increased screening coverage rate indicates consolida-
tion of the programme in Catalonia. The rate of Chagas 
disease congenital transmission in Catalonia is in 
accordance with the range in non-endemic countries.
Introduction
Chagas disease, a parasitic infection caused by the 
flagellated protozoan  Trypanosoma cruzi,  is endemic 
in Latin America [1]. It is found mainly in rural areas of 
Central and South America, except on the Caribbean 
islands, and coincides with the distribution of the vec-
tor that belongs to the family of triatomines and is 
responsible for transmission of the parasite to humans 
[2]. Other possible mechanisms of transmission are 
mother-to-child, blood transfusions, transplants of 
infected organs and tissues and ingestion of contami-
nated food [3]. There are an estimated 8 million people 
infected worldwide, of whom up to 30% may develop 
heart disease, with digestive or nervous system 
involvement in 10–20% [4-6].
Following migration from endemic areas to other 
countries, the epidemiological pattern of Chagas dis-
ease has changed in recent decades and new cases 
of congenital transmission and transmission by other 
mechanisms are detected in non-endemic countries 
[7]. The last decade (2000–2010) has seen an increase 
of people from endemic areas migrating to Europe 
[8]. In 2009, it was estimated that between 68,000 
and 122,000 people from endemic countries living in 
Europe were infected, although the rate of underdiag-
nosis was 94–96% [8]. European prevalence rates in 
migrants from endemic areas differ greatly according 
to the country of origin, with an estimated prevalence 
rate of 4.2%, which rises to 18.1% in migrants from 
Bolivia [9].
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Rates of congenital transmission in non-endemic coun-
tries are lower than those found in endemic countries 
[10] but the asymptomatic nature of the disease and 
the lack of knowledge about Chagas disease in non-
endemic countries make it difficult to detect new cases 
[11,12]. Screening newborns of positive mothers is key 
to the early detection and treatment of possible cases 
in non-endemic countries [13].
Spain, for cultural reasons, is the European country 
that has received most migrants from Latin America 
[14]. Screening for  T. cruzi  in blood and tissue banks 
has been mandatory by Royal decree-law since 2005 
[15] but legislation on the screening of congenital trans-
mission is still lacking [11].
In Catalonia, estimates of people infected with  T. 
cruzi  in 2010 were between 10,000 and 20,000, with 
between 203 and 387 pregnant women affected and 
between seven and 16 children with congenital Chagas 
disease [16]. After confirming the cost-effectiveness of 
a screening programme for congenital Chagas disease 
[17] and following the recommendations of the World 
Health Organization (WHO) in non-endemic countries 
which had to take appropriate measures to prevent 
and control vertical transmission [11,18,19], the Deputy 
director of public health surveillance and response to 
emergencies of the Public Health Agency of Catalonia 
(PHAC) has since 2010 progressively introduced and 
coordinated a protocol to detect, treat and cure cases 
of congenital Chagas disease [20].
There is no common legislation on the control of the 
congenital transmission of Chagas disease in Europe, 
although there are regional initiatives for the early 
detection and treatment of cases according to WHO 
recommendations. Official programmes for the detec-
tion and treatment of congenital Chagas disease have 
been introduced in the Valencia (2008) [21], Catalonia 
(2010) [20] and Galicia (2014) [22] regions in Spain and 
in Toscana (2012) [23] in Italy. Other regions do not 
have an official protocol but act locally in hospitals 
[19,24-26].
The objective of this study was to analyse the epidemi-
ological pattern of congenital Chagas disease in preg-
nant women from endemic areas and their children in 
the period from 2010 to 2015 in Catalonia and to evalu-
ate the coverage of the screening programme.
Methods
Surveillance setting
Catalonia is an autonomous community in the north-
east of Spain with more than 7.5 million inhabitants. 
In the study period (2010–2015), ca 450,000 people, 
6% of the population, were born in countries where 
Chagas disease is endemic [27]. There are 45 public 
and 30 private maternity hospitals in Catalonia and 
90% of births in Latin American women occur in public 
centres [28]. There are also 47 Sexual and Reproductive 
Health Care centres (Centre d’Atenció a la Salut Sexual 
I Reproductiva  - ASSIR), distributed in 372 maternal 
assistance points, which form part of the network of 
public primary care centres. In addition, there are 27 
microbiology laboratories able to perform diagnostic 
tests for Chagas disease [29].
Screening of pregnant women, newborns and 
their siblings
We introduced a surveillance system to evaluate the 
impact of congenital Chagas disease in Catalonia. The 
target population were pregnant women from endemic 
countries (first or second generation) and pregnant 
women from other origins (including Spain) who have 
lived in a rural area of an endemic country for more 
than one month at any point in their lives.
Serological screening is carried out during the first tri-
mester of pregnancy, although tests done at any time 
during pregnancy, delivery or after birth are included 
in the programme (Figure 1) [20]. The tests used for 
screening are those recommended by the WHO [1]. 
Samples are collected at the ASSIR centre during preg-
nancy or in hospitals during or after delivery. If the first 
test is positive, a second test using a different antigen 
or serological technique is carried out. If the results 
between the two tests are discrepant, a third serologi-
cal test, using a different technique, is carried out. All 
tests used in the programme follow the WHO recom-
mendation [1] and laboratories choose recommended 
tests according to their own experience and supplier. 
When the diagnosis is confirmed, it is recommended 
that pregnant women start treatment with trypano-
cidal drugs (benznidazole or nifurtimox) after birth 
and lactation, and before a possible new pregnancy. 
There is no risk of transmitting Chagas disease through 
breastfeeding.
Immediately after a birth to a mother diagnosed with 
Chagas disease, a clinical evaluation of the newborn 
is made in hospital to detect symptoms compatible 
with Chagas disease. The parasitological tests carried 
out during the first 48 h of life are the microhaemato-
crit and/or PCR [20]. If there is a positive PCR at birth, 
another PCR is carried out 4 weeks later to confirm 
the diagnosis. If any parasitological test is negative or 
tests cannot be carried out at birth, the infant is tested 
with a serological test after 9 months when maternal 
antibodies have waned. If this test is negative, the fol-
low-up ends and the child is considered not infected; 
if the test is positive, a second serological test with a 
different technique is carried out. If the results of the 
two tests are discrepant, a third serological test, using 
a different technique, is carried out. If any microhaem-
atocrit at birth, PCR at age 1 month or two serological 
tests after 9 months old are positive, T. cruzi infection is 
confirmed and antiparasitic treatment is administered.
The programme also includes other older children from 
positive mothers if they are living in Catalonia, using 
the same serological testing as for pregnant women. 
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Figure 1
Congenital Chagas disease screening programme in Catalonia, 2010–2015
Latin American pregnant woman (first or second generation)
First serological test 
Positive
Positive
Positive
Positive
Positive
Positive
Positive
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
First serological test 
Not infected Not infected
Second serological test 
Second 
serological test 
Second 
serological test 
Third
serological test 
Third
serological test 
Infected child or newborn
• Treatment
• Follow-up until serological negativity
Not infected
Not infected
Other children <18 years Newborns
Infected pregnant woman
• Treatment recommended after lactation
In the first 48 hours of life:
• Clinical examination
• Microhaematocrit and/or PCRa assay
From 9th month:
• First serological test
Third serological test 
a Many advances have been made in molecular biology and expert groups recommend PCR for the diagnosis in infants [28–30]. In case of 
positive PCR at birth, another PCR at age 1 month is necessary to confirm Chagas disease.
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When two serological tests using different technique 
are positive, T. cruziinfection is confirmed and antipar-
asitic treatment is administered.
The screening and follow-up of pregnant women, new-
borns and siblings are included in the public health 
portfolio and are free of charge.
Epidemiological surveillance
To implement the programme throughout the region, 
PHAC created the Working Group for Congenital Chagas 
disease in Catalonia, enrolling a large multidisciplinary 
group of Chagas disease experts who are responsible 
for the detection, notification and follow-up of positive 
pregnant women, newborns and siblings with positive 
mothers [16]: midwives, obstetricians, gynaecologists, 
paediatricians, microbiologists, specialists in infec-
tious diseases and internal medicine, community 
health workers and epidemiologists.
Surveillance includes the mandatory notification of 
confirmed  T. cruzi  cases through the Microbiological 
Reporting System of Catalonia, a network of Catalonian 
laboratories that collects and reports pathogens of 
public health importance to the PHAC [30]. Reported 
cases are included in the Voluntary Registry of 
Chagas Disease Congenital Cases in Catalonia (VRCH). 
Sociodemographic, diagnostic and treatment data and 
epidemiological information about the mothers (years 
living in Catalonia, the clinical form of Chagas disease 
and previous treatments for Chagas disease) are vol-
untarily collected by the Working Group and included 
in the VRCH.
Laboratories report annually the number of pregnant 
women screened. To calculate the coverage of the 
screening of pregnant women, the denominator was 
estimated taking into account the number of births 
in women from endemic countries in the Register of 
Newborns (an official regional registry linked to each 
maternity hospital, public or private, which collects 
information on births in Catalonia, including the moth-
ers’ country of origin [31]) and adding an estimation of 
pregnancies interrupted before giving birth (miscar-
riages and abortions) and women who moved away 
from Catalonia before childbirth as reported to the 
VRCH (13% of total pregnancies). Prevalence rates were 
calculated on pregnancies and not on pregnant women 
because the screening is repeated for each new preg-
nancy. To calculate the prevalence rates by country of 
origin we applied the distribution of births by mater-
nal country of origin in the Register of Newborns to the 
total of pregnancies screened.
Statistical analysis
All outcomes are shown in percentages and the annual 
percentage differences between 2010 and 2015 are 
shown as a relative change and evaluated using the Z 
score for two proportions of population.
Maternal epidemiological risk factors were evaluated 
between newborns with a definitive positive and nega-
tive diagnosis of Chagas disease. Continuous variables 
(age and years living in Catalonia) were transformed 
into categorical variables, choosing the mean as cut-
off point. Statistical significance was established 
assuming an α error of 0.05. Differences between 
groups were analysed by simple logistic regression and 
the results are shown as p value and odds ratio (OR). 
Multiple logistic regression was used to calculate the 
adjusted OR (aOR) and variables with a p value < 0.20 in 
the crude analysis were entered in the model. To avoid 
the problem of quasi-complete separation, Firth logis-
tic regression was used [32].
The analysis was performed using the Statistical 
Package for Social Sciences (SPSS v.25 for Windows).
Ethical statement
The study was not submitted for approval by a research 
ethics committee because the activities described 
were conducted as part of the legislated mandate of 
the Health Department of Catalonia, the competent 
authority for the surveillance of communicable dis-
eases according to Decree 203/2015 of 15 September, 
which created the epidemiological surveillance net-
work of Catalonia [30]. All the activities studied formed 
part of public health surveillance and did not require 
informed consent.
Results
Table 1 shows the overall results for screened pregnant 
women and follow-up in newborns and siblings.
Screening of pregnant women
It was estimated that 40,084 pregnant women should 
have been tested in Catalonia between 2010 and 2015. 
Of these, 33,469 (83.5%) were actually screened, an 
annual mean of 5,578 tests (Table 1). No positive cases 
were detected in pregnant women who were second-
generation migrants or travellers.
A total of 818 women were diagnosed with T. cruzi during 
pregnancy between 2010 and 2015: 707 (86%) became 
pregnant once, 103 twice (13%) and eight (1%) three 
times. In total, 937 pregnancies in positive women 
were followed between 2010 and 2015.
Screening coverage of pregnant women increased 
mainly between 2010 (68.4%) and 2011 (85.5%), when 
the logistics of the programme were introduced in all 
areas. The coverage gradually increased further until 
2015 (88.6%) (p < 0.001 between 2010 and 2015).
The highest density of Chagas-positive women was 
seen in the Barcelona health area (717 cases; 87.7%), 
especially in the Baix Llobregat (270 cases; 37.7%) and 
Barcelona (233 cases; 32.5%) areas (Figure 2).
During the study period, the prevalence rate was 2.8 
positive cases per 100 pregnancies screened (Figure 3). 
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The rates were highest in women from Bolivia (15.79), 
El Salvador (1.41) and Paraguay (1.24) (Table 2).
The mean age of positive women at pregnancy was 
33 years, which increased from 32 years in 2010 to 
34 years in 2015. Bolivian women represented 92.5% 
of the positive cases in whom the country of birth 
could be identified, followed by women from Paraguay 
(2.5%), Argentina (1.6%), Ecuador (0.9%), Honduras 
(0.7%), Chile (0.6%), El Salvador (0.5%), Peru (0.5%), 
Nicaragua (0.1%) and Colombia (0.1%). Almost half of 
the cases (47.6%) had arrived in Catalonia between 
2005 and 2006, and the mean number of years from 
arrival to pregnancy was 7 years (Table 2).
The main clinical form of Chagas disease was indeter-
minate (94.1%). Women with heart clinical form rep-
resented 3.8% of cases, while digestive and mixed 
pathologies (heart and digestive) accounted for 1.6% 
and 0.5% of cases, respectively. Only 26% of pregnant 
women received treatment with benznidazole or nifur-
timox before pregnancy. This percentage increased 
from 7.8% (7/90 cases with data about treatment) for 
pregnant women diagnosed in 2010 to 46.5% for those 
diagnosed in 2015 (33/71 cases with data about treat-
ment) (p < 0.001).
Pregnancies were interrupted in 9.3% (n = 87) of preg-
nancies. More than half were miscarriages (65.5%), 
followed by abortions (23%) and cases where the rea-
son for interruption was missing (11.5%), while 4.1% of 
pregnant women left Catalonia before childbirth, which 
meant that follow-up of the newborn was not possible.
There were 812 births from 937 pregnancies in 818  T. 
cruzi-positive women in Catalonian maternity hospitals 
(Table 1).
Follow-up of siblings
For 674 of the 818  T. cruzi-positive women (82.4%) 
detected by the programme, it was possible to deter-
mine whether they had other children born before the 
current pregnancy and living in Catalonia, and 359 
(53.3%) had at least one. The mean of other children 
per mother was 0.8. We identified 519 children for 
screening. In most cases, the children had not been 
tested or testing information not notified by the work-
ing group (341 cases; 65.7%), ranging from 93.1% in 
2010 to 49.3% in 2015 (p < 0.001). Of the 178 children 
who were successfully screened and reported (34.3%), 
14 were positive (7.9%) (Table 1). The median age of 
those 14 children was 10 years (range: 3–18 years) 
and 12 were male. Five of them were born in Catalonia 
between 2005 and 2008 but were not tested during the 
first year of life, while nine arrived in Catalonia during 
childhood. All 14 cases started treatment with benz-
nidazole, but treatment was interrupted in two cases 
because of side effects such as neutropenia and toxi-
coderma and was not resumed, although the follow-up 
continued. In seven of the 14 cases, the follow-up was 
not completed with the required serological test. None 
of the seven children who continued the follow-up 
had negative serological tests after treatment, with a 
median follow-up of 4 years (range: 1–6 years) (Table 
3).
Follow-up of newborns
Of the 812 newborns, 728 (89.7%) were tested for  T. 
cruzi  parasite at birth. The most frequent tests were 
PCR (87.1%) and microhaematocrit (57.6%). In 84 of 
812 cases (10.3%) the newborn was not tested at birth 
(16.8% in 2010 and 6.9% in 2015; p = 0.029). Testing 
after age 9 months was carried out in 672 of 812 
newborns (82.8%). Of these, 95.8% (n = 644) tested 
negative. The median age at screening was 10 months 
(Table 1).
A total of 140 newborns (17.5%) did not complete 
the follow-up. The main reason was the departure of 
the family from Catalonia before the newborn was 9 
months old (7.0%), followed by failure to attend the 
medical visit (6.6%) and failure of the surveillance cir-
cuit (3.9%).
Twenty-eight cases were diagnosed with  T. 
cruzi  infection acquired through congenital 
transmission (4.2%). In 27 cases, the mother was from 
Bolivia and in one case from Paraguay. Twelve infants 
were diagnosed by parasitological tests before age 9 
months and 16 infants with serological tests after age 
9 months (Table 3). In four of 28 cases, the newborn 
presented symptoms compatible with Chagas disease, 
including splenomegaly (3/4), hepatomegaly (3/4) and 
jaundice (3/4).
All 28 positive cases were treated with benznidazole. 
Treatment was suspended because of failure to attend 
follow-up visits in one case and because of an adverse 
reaction in one case. Overall, four of 28 newborns had 
adverse reactions, including increased transaminases 
(n = 1), pancytopenia (n = 1), cessation of weight gain 
(n = 1) and anorexia (n = 1). Serology after treatment 
was negative in 15 cases, with a mean time between 
treatment end and serology of 8.1 months (range: 0–21 
months). Two newborns treated before age 12 months 
did not become seronegative: the first was diagnosed 
by PCR 1 month after birth and remained positive 1 year 
after treatment. Treatment was repeated 4 years later 
and the subsequent PCR was negative, but serologi-
cal testing was not carried out. The second child had 
a negative PCR at birth, but positive PCR and serol-
ogy at 9 months. Treatment was stopped after 10 days 
because of pancytopenia and was resumed 2 months 
later. Two years later serology remained positive.
Recovery rates were 89% for newborns treated before 
6 months of age, 80% for those treated between 6 
and 12 months of age and 20% after 12 months of age. 
Taking the serological diagnosis after 9 months as the 
gold standard, the sensitivity of the microhaematocrit 
and PCR was 29.4% and 52.6%, respectively, and the 
specificity 100% and 99.2% (in four cases, PCR was 
positive at birth but negative after 1 month).
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Analysis of maternal risk factors
In an analysis of maternal risk factors for vertical trans-
mission of the infection, we saw significant differences 
between positive and negative siblings (aOR = 22.79; 
95% confidence interval (CI): 3.75–161.54) and between 
heart and indeterminate clinical forms (aOR = 14.4; 
95% CI: 2.11–87.67) (Table 2). Differences between 
untreated and treated mothers showed crude statisti-
cal significance (p = 0.033) but significance was lost 
after adjusting for multivariate logistic regression 
(aOR = 6.67; 95% CI: 0.78–876.89). Other risk factors 
analysed, such as the mother’s age, country of origin 
or time living in Catalonia (≤ 7 years) had no significant 
influence on the likelihood of vertical transmission.
Discussion
The congenital Chagas disease prevention and control 
programme in Catalonia is one of few screening pro-
grammes for the control of congenital Chagas disease 
launched by public health authorities in a non-endemic 
region [9].The observed prevalence of Chagas disease 
(2.8 cases/100 pregnancies) was similar to that found in 
other studies in pregnant women in Catalonia [33, 34]. 
The prevalence in Bolivian pregnant women was lower 
(15.8%) than in a similar programme in Bolivia (23.3%) 
[35]. Studies in other regions in Spain show higher 
prevalence rates in Valencia (34.1%) [36] and Vizcaya 
(22%) [37] but lower rates in Madrid (11.4%) [38] and 
Almeria (12.5%) [39]. Other non-endemic countries 
show lower rates in Bolivian pregnant women living 
in Italy (8.7%) [25] and Switzerland (8.8%) [24]. These 
differences may be due, in part, to methodological 
differences in estimating the rates. The prevalence 
rates observed in our programme in women from 
other endemic countries such as Paraguay, Argentina, 
Ecuador, Honduras, Chile, el Salvador, Peru, Nicaragua 
and Colombia (range: 0.02–1.41), were much lower 
than those detected in other Spanish studies (range: 
0.2–7.4) [36,40] or in studies from the endemic coun-
tries themselves (range: 3.2–12.7) [41-45].
The rate of congenital transmission in Catalonia (4.17%) 
was within the range detected in endemic (range: 1.7–
5) [35,46-50] and non-endemic countries (range: 0–7.3) 
[25,33,34,36-38].
The estimated screening coverage rate in pregnant 
women was 83.5%, which is lower than the rate found 
in Valencia (94.5%) [36]. This may be due, in part, to 
the greater centralisation and smaller number of cen-
tres included in the Valencia programme (three mater-
nity hospitals) compared with Catalonia (45 public 
maternity hospitals and 372 primary health centres 
with midwife care, including all public health centres).
Screening of the newborns’ siblings is widely neglected 
in gestational screening programmes and there are few 
studies of this subgroup [51-53]. A prevalence study 
conducted in Catalonia in children younger than 18 
years with a Chagas disease-positive mother [53] found 
a slightly higher rate (10.9%) than ours (7.3%), and a 
clinical study of children in Catalonia and Switzerland 
identified a higher percentage of adverse effects dur-
ing treatment (36%) than our programme (14.3%) and 
a recovery rate at age 2 years of 17.2%, compared with 
0% in our programme [51]. Although the screening of 
other children improved significantly between 2010 
(6.9%) and 2015 (50.7%), the high percentage of miss-
ing cases (352 cases, 66.4%), and the missing follow-
up in positive cases (50%) demonstrate a lack of a 
well-established notification and follow-up circuit for 
this subgroup.
Parasitological testing at birth improved significantly 
between 2010 (83.2%) and 2015 (93.1%). PCR was used 
more than the microhaematocrit (87.1% and 57.6%, 
respectively), and the microhaematocrit was less fre-
quent in 2015 than in 2010 (57.4% vs 77.7%). This 
confirms the greater practicality of PCR in our region. 
Even if PCR is widely accepted for the early diagnosis 
of Chagas disease [54-56], false positive (four cases) 
and false negative results (nine cases) indicate that a 
standardised PCR technique with higher sensitivity is 
required [57]. Currently, it is still necessary to wait until 
age 1 month to validate the diagnosis by PCR or to per-
form a serological test after 9 months for PCR-negative 
cases [58].
We detected some delay between diagnosis and start of 
treatment for positive newborns. There are several pos-
sible explanations: the presence of other pathologies 
Figure 2
Geographical distribution of Trypanosoma cruzi-positive 
pregnant women and cases of congenital transmission, 
Catalonia, 2010–2015 (n = 818)
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that require other incompatible treatments, difficulty in 
obtaining the medication (there was a significant lack 
of supply of Benznidazole a few years ago) or a deci-
sion made by the patient’s family.
The recovery rates observed in treated newborns are 
provisional data because newborns with positive serol-
ogy will be followed until serology is negative and the 
results could therefore change in the future. Sometimes 
problems with treatment compliance or adverse reac-
tions can affect seronegativisation in post-treatment 
follow-up. However, although our results are based 
on very few cases, the current results suggest that it 
is very important to detect the infection before age 
12 months to achieve a probability of cure of more 
than 80%. Schijman et al. found a 100% recovery rate 
when treatment is started before age 6 months com-
pared with 88.9% in our study [59].
With respect to maternal epidemiological risk factors 
for congenital transmission, we found three studies 
that showed an increased risk of congenital transmis-
sion in untreated women [60-62]. In our study, women 
untreated before pregnancy had an almost sevenfold 
greater probability of congenital infection but the 
adjusted significance was weak (p = 0.093). Having the 
heart clinical form of Chagas disease rather than the 
indeterminate clinical form and having other infected 
children increased the risk of congenital transmission 
14 and 23 times, respectively. These findings demon-
strate the importance of recommending treatment of 
women of childbearing age before a new pregnancy, 
especially in those who already have infected children 
or those with the heart clinical form of the disease.
Other studies in Catalonia found a higher proportion 
of the digestive clinical form (up to 21% vs 1.6%) [5,6]. 
Our results may be an underestimate because infected 
women diagnosed during pregnancy could not undergo 
specific radiological tests to detect possible digestive 
disorders.
The main challenge of our programme was to calculate 
the coverage of screening for pregnant women and the 
prevalence rate by country of origin, because the pro-
tocol did not plan for quantifying the target population 
and collecting epidemiological information on pregnant 
women with negative results. To solve this limitation, 
we used the Register of Newborns as a source. It will be 
necessary to involve the ASSIR centres in reporting all 
cases, negative or positive, or create an improved data 
collection system to provide this information. Another 
limitation of the programme were the 10.5% missing 
numbers in the follow-up at age 9–12 months owing to 
failures in the follow-up circuit such as a lack of aware-
ness about Chagas disease among paediatricians and 
patients, or a missing patient referral. The percentage 
lost to follow-up was smaller in 2013 (6.5%) and 2014 
(2.4%) because of a specific community health action 
to redirect lost cases [63]. It is therefore necessary to 
improve primary healthcare circuits to control the new-
borns and other children of positive mothers and to 
add community health actions to the surveillance of 
congenital Chagas disease.
Figure 3
Annual number of screened women and Trypanosoma cruzi-positive pregnant women, Catalonia, 2010–2015 (n = 33,469)
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Table 2
Epidemiological characteristics, prevalence rates by endemic country of origin and maternal risk factors for congenital 
Chagas disease, Catalonia, 2010–2015 (n = 818)
Maternal risk factors
Positive 
pregnant 
women 
(n = 818)
Prevalence rates 
for country of 
origina
Completed 
follow-up 
negative in 
newborns 
(n = 644)
Completed 
follow-up 
positive in 
newborns 
(n = 28)
Crude p 
value
Crude OR 
(CI)
Adjusted p 
valueb
Adjusted 
OR (CI)b
n % n % n %
Age
 < 33 years 389 47.6 305 47.4 17 60.7 0.166
1.71 
 
(0.79–
3.72)
0.693
1.30 
 
(0.35–5.28)
 ≥ 33 years 429 52.4 339 51.6 11 39.3 Ref
Previous treatmentc
Yes 115 26.0 107 29.9 2 8.3 Ref
No 328 74.0 251 70.1 22 91.7 0.033
3.85 
 
(1.02–
14.49)
0.093
6.67 
 
(0.78–
876.89)
Country of birthd
Bolivia 755 92.5 15.79 598 92.9 27 96.4 Ref
Paraguay 20 2.5 1.24 17 2.6 1 3.6 0.801
1.30 
 
(0.17–
10.15)
NA
Argentina 13 1.6 0.52 11 1.7 0 0 NA
Ecuador 7 0.9 0.10 4 0.6 0 0 NA
Honduras 6 0.7 0.26 4 0.6 0 0 NA
Chile 5 0.6 0.50 1 0.2 0 0 NA
El Salvador 4 0.5 1.41 3 0.5 0 0 NA
Peru 4 0.5 0.11 4 0.6 0 0 NA
Nicaragua 1 0.1 0.57 1 0.2 0 0 NA
Colombia 1 0.1 0.02 1 0.2 0 0 NA
Clinical form of Chagas diseasee
Indeterminate 524 94.1 432 94.9 23 88.5 Ref
Heart 21 3.8 15 3.3 3 11.5 0.047
3.76 
 
(1.02–
13.90)
0.009
14.40 
 
(2.11–
87.67)
Digestive 9 1.6 8 1.8 0 0 NA
Mixed 3 0.5 0 0 0 0 NA
Siblings completing follow-upf
Negative 131 92.3 150 97.4 4 40 Ref
Positive 11 7.7 4 2.6 6 60 < 0.001
56.25 
 
(11.26–
280.9)
0.001
22.79 
 
(3.75–
161.54)
Years living in Cataloniag
≤ 7 years 254 57.9 186 49.7 12 75 0.059
3.03 
 
(0.96–
9.57)
0.453
1.76 
 
(0.42–
10.05)
 > 7 years 185 42.1 188 50.3 4 25 Ref
CI: confidence interval; NA: Not Applicable; OR: odds ratio; Ref: reference value.
a Number of positive newborns per 100 births, adjusted by pregnant women screening coverage rate.
b Firth multiple logistic regression.
c Unknown data: n = 375 (45.8%).
d Unknown data: n = 2 (0.2%).
e Unknown data: n = 261 (31.9%).
f Mothers without other children and with untested other children: n = 676 (82.6%).
g Unknown data: n = 379 (46.3%).
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Table 3
Positive Trypanosoma cruzi diagnostic tests, treatment and follow-up in newborns and their siblings, Catalonia, 2010–2015 
(n = 42)
ID Microhaematocrit PCR Serology Country of birth
Age of 
arrival
Age at 
diagnosis 
(months)
Age at 
treatment 
start 
(months)
Symptoms 
compatible 
with Chagas 
disease
Adverse 
reactions 
to 
treatment
Completed 
treatment
Serological 
negativisation
Follow-up 
after 
treatment 
end 
(months)
Newborns
1  +  + NA
NA NA
0 2 No No Yes Yes 1
2  +  + NA 0 0 Yes Yes No Yes 9
3  +  + NA 0 0 Yes No Yes Yes 9
4 −  + NA 0 1 No No Yes Yes 1
5  + NP NA 0 0 Yes No Yes Yes 6
6 NP  + NA 0 0 No No Yes Yes 21
7 −  + NA 1 2 No No Yes Yes 6
8 NP  + NA 1 4 No No Yes Yes 6
9 −  + NA 1 1 No No Yes No 34
10  + NP NA 1 3 No No Yes Yes 3
11 −  + NA 2 15 No No Yes No 11
12 NP  + NA 6 6 No No Yes Yes 12
13 NP −  + 9 9 No No Yes Yes 5
14 − NP  + 9 10 No No Yes Losta NA
15 NP NP  + 9 9 No No Yes Yes 0
16 − NP  + 9 11 No No Yes Yes 9
17 NP −  + 9 9 No Yes Yes No 24
18 − −  + 10 11 No No Yes Losta NA
19 − −  + 11 12 No No Yes No 33
20 NP NP  + 11 11 No No Yes No 59
21 − −  + 12 13 No Yes Yes Yes 18
22 − NP  + 12 12 Yes No No Losta NA
23 − −  + 13 12 No No Yes No 35
24 NP −  + 15 16 No No Yes Yes 16
25 NP NP  + 20 24 No No Yes No 28
26 NP NP  + 20 21 No No Yes No 30
27 − −  + 23 23 No No Yes No 4
28 NP −  + 27 28 No Yes Yes No 27
Median (interquartile range) 9 (11) 9.5 (10.75) 11.5 (21.75)
Siblings
1
NA NA
 + Spain NA 3 3 No No Yes No 4
2  + Spain NA 4 5 No No Yes No 4
3  + Spain NA 4 4 No No Yes No 1
4  + Bolivia 7 5 5 No No Yes No 6
5  + Spain NA 7 7 No Yes No Losta NA
6  + Bolivia 1 7 8 No Yes No Losta NA
7  + Spain NA 9 9 No No Yes No 3
8  + Bolivia 9 11 11 No No Yes Losta NA
9  + Bolivia 9 11 11 No No Yes Losta NA
10  + Bolivia 6 11 11 No No Yes No 2
11  + Bolivia 10 12 12 No No Yes Losta NA
12  + Bolivia 13 13 14 No No Yes Losta NA
13  + Bolivia 9 16 16 No No Yes No 5
14  + Bolivia 15 18 18 No No Yes Losta NA
Median (interquartile range) 10 (7.5) 10 (7.5) 4 (3)
+: positive; −: negative; ID: identification number; NP: not performed; NA: not applicable.
a Lost to follow-up before serological control.
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Conclusion
The results of the congenital Chagas disease pro-
gramme in Catalonia show that systematic control of 
the congenital transmission of Chagas disease by an 
integrated public health surveillance system is pos-
sible in a non-endemic region and the increase in the 
estimated screening coverage rate indicates its consol-
idation in Catalonia.
Prevalence and congenital transmission rates were 
within the ranges detected in other studies conducted 
in non-endemic settings. Having previous children with 
Chagas disease and presenting the heart clinical dis-
ease form of the disease were risk factors for the con-
genital transmission of T. cruzi. Treatment of women of 
childbearing age with these characteristics is recom-
mended in order to improve the treatment of Chagas 
disease in non-endemic countries.
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